Reconstruction of cancer cell lineage history in patients with MPN
The JAK2 V617F mutation is common in the majority of Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), where the activation of JAK2 signaling triggers the...
DRSS: A new disease risk stratification system for hematologic malignancies
The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is largely dependent upon disease type and remission status before transplant
"In the MPN Hub, we have gathered the most recent and most relevant information about MPN pathophysiology, clinical advances, and therapy. You are sure to find a response to your burning questions about MPN here!"